摘要
目的进一步研究胃肠道间质瘤（GIST）肝转移患者的临床治疗效果及其影响因素，探索合理的临床治疗方案。方法回顾性分析2007年4月至2010年4月解放军总医院收治的24例伴肝转移的GIST患者的临床资料。结果GIST伴肝转移患者的1、2、3、4年累积生存率分别为91％、72％、22％、6％。术后服用伊马替尼患者1、2、3年生存率分别为91％、70％、28％，中位生存时间为26个月，死亡率为27．3％（3／11），其中肿瘤完整消除患者9例。GIST肝转移术后未服用伊马替尼患者1、2、3年生存率分别为90％、68％、18％，中位生存期为24个月，死亡率为14．3％（2／13），其中肿瘤完整消除患者12例。GIST伴肝转移的患者完整切除术后复发率为28．6％（4／14），死亡率为7．1％（1／14）。GIST肝转移的患者未完整切除术后死亡率为40％（4／10）。结论采用外科方法消除原发灶和转移灶以及术后应用伊马替尼常规治疗能明显延长GIST肝转移患者的生存时间，减少术后复发率，提高生命质量，是GIST肝转移患者的有效治疗方案。
Objective To analyze the clinical characters, treatment effects and influential factors of gastrointestinal stromal tumor patients with hepatic metastases, and to explore the reasonable clinical treatment protocols. Methods The clinical data of 24 gastrointestinal stromal tumor patients with hepatic metastases who were admitted to Peoples Liberation Army Hospital from April 2007 to April 2010 were retrospectively analyzed. Results The 1-, 2-, 3- and 4-year cumulative survival rates of hepatic metastases patients with gastrointestinal stromal tumors were 91%, 72 %, 22 % and 6 %, respectively. The 1-, 2- and 3- year survival rates of the patients treated with imatinib after operation were 91%, 70 %, 28 %, respectively, the median survival time was 26 months, the mortality rate was 27.3 % （3/11）, and 9 cases got the tumor complete elimination. The 1-, 2- and 3-year survival rates of the patients treated without imatinib after operation were 90 %, 68 %, 18 %, respectively, the median survival time was 24 months, the mortality rate was 14.3 % （2/13）, and 12 eases got the tumor complete elimination. The recurrence rate after complete resection was 28.6 % （4/14）, and the mortality rate was 7.1% （1/14）. The mortality rate after incomplete resection was 40 % （4/10）. Conclusion Surgical treatment of eliminating the primary and metastatic lesion, and adjuvant therapy of imtinib could prolong the survival time, reduce postoperative recurrence rate and improve the quality of life, which are the effective methods for the treatment of the gastrointestinal stromal tumor patients with hepatic metastases.
出处
《肿瘤研究与临床》
CAS
2015年第11期760-762,770,共4页
Cancer Research and Clinic
关键词
胃肠道间质肿瘤
肝转移
治疗
伊马替尼
Gastrointestinal stromal tumors
Hepatic metastatic
Therapy
Imatinib
